Hoffmann-la Roche Inc.

Indiana University

Anish A Konkar

Jefferson Wright Tilley

Nader Fotouhi

Waleed Danho

Rebecca Taub

Joseph Swistok

Wajiha Khan

David Charles Fry

George Kenneth Ehrlich

Karin Conde-Knape

Cristina Martha Rondinone

Richard Dennis DiMarchi

Konrad H Bleicher

Eric Argirios Kitas

Eike Hoffmann

Sara Belli

Herein is reported a fusion polypeptide comprising i) one, two, three or four incretin receptor ligand polypeptides, and ii) one human immunoglobulin Fc-region, wherein at least one of the incretin receptor ligand polypeptides comprises an amino acid that is covalently conjugated to a lipid, and wherein each of the one, two, three or four incretin receptor ligand polypeptides is covalently conjugated by a peptide bond to a terminus of the human immunoglobulin Fc-region, whereby to each terminus of the human immunoglobulin Fc-region only a single incretin receptor ligand polypeptide is conjugated.

Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides

Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa). These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.

Neuropeptide-2 receptor (Y-2R) agonists and uses thereof

Growing community of inventors

North Bethesda, MD, United States of America

Anish A Konkar